Once considered rare and untreatable, amyloid transthyretin (ATTR) amyloidosis with cardiomyopathy (ATTR-CM) has increased in incidence over the last decade and is now a treatable condition. This is partly due to our better understanding of the biology of the disease and recognition of its comorbid or co-occurring conditions in both cardiac and noncardiac patients with cardiac amyloidosis. In an open discussion, chairperson Martha Grogan, MD, and faculty members Marianna Fontana, MD, and Nitasha Sarswat, MD, provide an updated review of the disease state that includes a better understanding of the mechanism of the disease, discuss the pathogenic and protective genetic variants, and examine evidence from clinical trials that are impacting the evolving landscape.
Treating ATTR-CM With a Novel Therapeutic Approach: Understanding the ATTRibutes to Success
Disclosure of Conflicts of Interest
In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.
Host:
Martha Grogan, MD, FACP, FACC
Director, Cardiac Amyloid Clinic
Associate Professor of Medicine
Department of Cardiovascular Diseases
Mayo Clinic
Rochester, MNConsulting Fees: AstraZeneca, Janssen, Novo Nordisk, Prothena
Research: Alnylam, BridgeBio, Eidos, Janssen, Novo Nordisk, PfizerFaculty:
Marianna Fontana, MD
Director of the UCL CMR Unit, Royal Free Hospital
Professor of Cardiology and Honorary Consultant Cardiologist
National Amyloidosis Centre, Division of Medicine
University College of London
London, UKConsulting Fees: Akcea, Alexion, Alnylam, AstraZeneca, Attralus, Intellia, Ionis, Janssen, Novo Nordisk, Pfizer, Prothena
Research: Alnylam, Eidos, PfizerNitasha Sarswat, MD
Director, Infiltrative Cardiomyopathy Program
Advanced Heart Failure, Mechanical Circulatory Support and Transplantation
University of Chicago Hospital
Chicago, ILConsulting Fees: Alnylam, BridgeBio, Pfizer
Research: PfizerReviewers/Content Planners/Authors:
- Cindy Davidson has nothing to disclose.
- Ann Early has nothing to disclose.
- Howard Green has nothing to disclose.
- Andrea Mathis has nothing to disclose.
- Tim Person has nothing to disclose.
- Mario Trucillo, PhD, MS, has nothing to disclose.
Learning Objectives
After participating in this educational activity, participants should be better able to:
Describe the pathophysiology and genetic variations of amyloid transthyretin amyloidosis with cardiomyopathy (ATTR-CM)
Discuss the clinical manifestations and diagnosis of ATTR-CM
Compare the treatment options available for patients with ATTR-CM
Target Audience
This activity is designed to meet the educational needs of cardiologists, cardiology nurse practitioners, physician associates, and nurses.
Accreditation and Credit Designation Statements
In support of improving patient care, Global Learning Collaborative (GLC) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
Global Learning Collaborative (GLC) designates this enduring activity for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Global Learning Collaborative (GLC) designates this activity for 0.25 nursing contact hours. Nurses should claim only the credit commensurate with the extent of their participation in the activity.
Provider(s)/Educational Partner(s)
Our ultimate goal is to improve the care being delivered to patients, and our high-quality, evidence-based CME initiatives reflect our dedication to the creation and execution of excellence and are the product of shared research, knowledge, and clinical practice skills across the healthcare continuum.
Commercial Support
This activity is supported by an independent educational grant from BridgeBio.
Disclaimer
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Medtelligence. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to access a site outside of Medtelligence you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.
Reproduction Prohibited
Reproduction of this materialis not permitted without written permission from the copyright owner.Publication Dates
Release Date:
Expiration Date:
Ready to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!
Recommended
Raymond Townsend, MD
Melissa Magwire, RN, MSN
Michael Weber, MD
Christina Economides, MD
Brian Howard, MD
David N. Kenigsberg, MD, FACC